Last updated on April 2019

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata


Brief description of study

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.

Clinical Study Identifier: NCT03570749

Contact Investigators or Research Sites near you

Start Over

Stanford Health Care

Redwood City, CA United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

Medaphase Inc

Newnan, GA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Dermatology Specialist

Louisville, KY United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Dermatology Associates

Seattle, WA United States
  Connect »

GCM Medical Group PSC

San Juan, Puerto Rico
  Connect »

Mosaic Dermatology

Santa Monica, CA United States
  Connect »

Johnson Dermatology

Fort Smith, AR United States
  Connect »

Howard University Hospital

Washington, WA United States
  Connect »

Clarkston Skin Research

Clarkston, MI United States
  Connect »

Park Avenue Dermatology

Orange Park, FL United States
  Connect »

Dermatology Research Associates

Los Angeles, CA United States
  Connect »

Bellaire Dermatology

Bellaire, TX United States
  Connect »

Center for Clinical Studies

Houston, TX United States
  Connect »

Stephen L Miller, MD, PA

San Antonio, TX United States
  Connect »

Center for Clinical Studies

Webster, TX United States
  Connect »

Inha University Hospital

Jung-gu, Korea, Republic of
  Connect »

Chonbuk National University Hospital

Jeon Ju-City, Korea, Republic of
  Connect »

Konkuk University Hospital

Seoul, Korea, Republic of
  Connect »

Alliance Research Centers

Laguna Hills, CA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.